MDlive.net
Schedule of Events MDwebNews About Us Banner
 
New Therapies for Psoriasis

Dr. Lebwohl reviews the new biologic agents that are being introduced for the treatment of psoriasis. The advantages and disadvantages of each of the agents are discussed.

Mark Lebwohl, MD
Mark Lebwohl, MD, has been practicing dermatology since 1983. He is a professor of dermatology and chairman of the department of dermatology at the Mount Sinai School of Medicine. Dr. Lebwohl is President of the New York State Society of Dermatology, and has served as president of the Manhattan Dermatologic Society and chairman of the Dermatology Section of the New York Academy of Medicine. Dr. Lebwohl is the current chairman of the Psoriasis Task Force of the American Academy of Dermatology, and has directed the AAD's annual Psoriasis Symposium, Diagnostic Update Symposium, Therapeutics Symposium, and the patient viewing session. He is a member of the Scientific Assembly Council and chaired Academy 2001 in California.

Dr. Lebwohl is a member of the medical advisory board of the National Psoriasis Foundation and editor of Psoriasis Forum as well as medical editor of The Bulletin of the National Psoriasis Foundation. He is the "Medical Pearl" feature editor as well as assistant editor of The Journal of the American Academy of Dermatology. He has chaired numerous symposia and has written or edited several books including Difficult Diagnoses in Dermatology, Psoriasis, and Atlas of the Skin and Systemic Disease. Dr. Lebwohl has authored or co-authored over 400 publications including articles, chapters and abstracts. He is actively involved in clinical trials of new dermatologic treatments.